Whole Healthcare Magazine

BioViva: Global Leaders of
Pioneering Platform for Gene and
Cell Therapeutics
In this digital era, where health information
is available at the fingertips, tech-savvy
people are looking at expert advice and
proactive care from the health industry. And
moving from treatment to preventive
scenarios, life sciences companies are trying
to keep the beat with people. With changing
circumstances big data is playing a vital role
in the health industry, and understanding the
big picture of its importance in medicine and
recognizing the real-world applications of data
analytics as they’re being used today is
crucial.
Pointing analogous in today’s data driven
medicine Elizabeth Parrish the Founder &
CEO of BioViva asserts - “We are focused on
saving as many lives as possible by making
tomorrow’s therapies available today. This is
about Life and Death. Risk aversion and
delaying the approval of therapies that have
been successful in research kills.” Also, she is
actively dedicated to safeguarding healthy
longevity for all.
Elizabeth Parrish is a humanitarian,
entrepreneur, innovator, author, podcaster, and
a leading voice for genetic cures. As a
proponent of progress and education for the
advancement of regenerative medicine
modalities, she serves as a motivational
speaker to the public for the life sciences. She
is actively involved in international
educational media outreach.
Under the leadership of Elizabeth, BioViva
is collecting as much data, both from people
all over the world who have had their
genomes and epigenomes analysed with
company’s products as well as patients
participating in the cutting edge trials offered
by its partner company, Integrated Health
Systems. These data sets will be anonymized
and made available to labs and drug
companies worldwide to speed up research
and development in the area of longevity
medicine.
Groundbreaking Gene Therapies
Unlike many biotech companies, BioViva is
motivated as much by compassion, a concern
for others, and the necessity to create a kinder
world with less suffering, as by financial gain.
And it is the first to partner with a company
that offers groundbreaking gene therapies
designed to address the issues of aging to
consensual patients in need. These therapies
had already proven successful in animal
models.
‘Passion is The Key for Success’
Passionate enough to cope with little funding
and considerable resistance from the medical
and scientific community, Elizabeth believes
that passion is her strength. It has given her
the energy to continue even when criticism
was unfair, rooted in ignorance and closed
mindsets.
This passion also drove her for trial therapy
in Bogota in 2015 on herself, although it had
already been successful in animal models, she
wanted to be sure it was safe for humans.
31 |
The 30
Healthcare
El tes